Perrigo (NYSE:PRGO) Shares Gap Down After Earnings Miss

Perrigo Company plc (NYSE:PRGO) gapped down before the market opened on Thursday following a dissappointing earnings announcement. The stock had previously closed at $14.41, but opened at $13.30. Perrigo shares last traded at $13.7290, with a volume of 906,929 shares changing hands.

The company reported $0.77 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.80 by ($0.03). Perrigo had a negative net margin of 1.21% and a positive return on equity of 9.16%. The company had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.09 billion. During the same quarter last year, the business earned $0.93 EPS. The firm’s revenue for the quarter was down 2.5% compared to the same quarter last year. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS.

Perrigo Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 24th. Shareholders of record on Monday, March 2nd will be paid a dividend of $0.29 per share. The ex-dividend date of this dividend is Monday, March 2nd. This represents a $1.16 annualized dividend and a yield of 8.2%. Perrigo’s dividend payout ratio (DPR) is -305.26%.

Perrigo News Roundup

Here are the key news stories impacting Perrigo this week:

• Positive Sentiment: Revenue slightly beat analyst expectations for Q4 at $1.11B (consensus ~$1.09B), showing resilience in top-line despite soft category demand. Press Release / Slide Deck
• Positive Sentiment: Management launched an operational enhancement program expected to deliver $80–$100M of pre-tax annualized savings, which could support margin recovery over time. PR Newswire Release
• Neutral Sentiment: Company introduced a new reporting structure and a “CORE” outlook (excludes infant formula and certain divestitures), improving operating clarity but reducing near-term comparability to prior periods. Earnings Presentation
• Negative Sentiment: Q4 EPS missed consensus: $0.77 reported vs. $0.80 expected and down from $0.93 a year ago—an earnings shortfall that pressured sentiment. Zacks: Q4 Earnings Lag
• Negative Sentiment: FY2026 “all-in” guidance came in below Street expectations: EPS guide of $2.25–2.55 (consensus ~2.70) and revenue guide toward the low end of $4.0–4.2B. Lower-than-expected guidance is the main near-term driver of the stock pullback. PR Newswire Release
• Negative Sentiment: Organic net sales declined ~4.5% year-over-year (overall net sales -2.5%), highlighting persistent demand weakness in some categories. PR Newswire Release

Wall Street Analyst Weigh In

PRGO has been the topic of a number of research analyst reports. Weiss Ratings reissued a “sell (d+)” rating on shares of Perrigo in a research report on Monday, December 22nd. Wall Street Zen cut Perrigo from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. JPMorgan Chase & Co. cut their price objective on Perrigo from $20.00 to $18.00 and set a “neutral” rating on the stock in a report on Monday, December 15th. Canaccord Genuity Group decreased their target price on Perrigo from $40.00 to $20.00 and set a “buy” rating on the stock in a research note on Thursday, November 6th. Finally, Jefferies Financial Group reaffirmed a “hold” rating on shares of Perrigo in a research report on Thursday. One analyst has rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Perrigo currently has a consensus rating of “Hold” and an average price target of $20.33.

Institutional Trading of Perrigo

Several hedge funds have recently made changes to their positions in PRGO. Amundi lifted its holdings in Perrigo by 11.7% in the first quarter. Amundi now owns 5,292 shares of the company’s stock valued at $148,000 after acquiring an additional 556 shares during the period. Goldman Sachs Group Inc. increased its holdings in shares of Perrigo by 126.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,159,768 shares of the company’s stock valued at $32,520,000 after purchasing an additional 647,982 shares in the last quarter. United Services Automobile Association acquired a new stake in shares of Perrigo in the first quarter valued at about $250,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Perrigo by 6.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 513,112 shares of the company’s stock worth $14,388,000 after buying an additional 32,151 shares in the last quarter. Finally, Geneos Wealth Management Inc. grew its position in Perrigo by 439.1% during the first quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock worth $27,000 after buying an additional 786 shares during the period. Institutional investors and hedge funds own 95.91% of the company’s stock.

Perrigo Stock Performance

The stock’s fifty day simple moving average is $14.41 and its 200-day simple moving average is $17.55. The company has a quick ratio of 1.44, a current ratio of 2.51 and a debt-to-equity ratio of 0.81. The company has a market capitalization of $1.95 billion, a PE ratio of -37.32, a PEG ratio of 1.29 and a beta of 0.39.

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.